An Error Occurred: Forbidden

Oops! An Error Occurred

The server returned a "403 Forbidden".

Something is broken. Please let us know what you were doing when this error occurred. We will fix it as soon as possible. Sorry for any inconvenience caused.
Børs og finans

Fersk oppdatering fra Bergenbio

Bergenbio presenterer nå resultater i Tyskland.

Foto: Konstantin Kolosov / Shutterstock / NTB scanpix

Foto: Konstantin Kolosov / Shutterstock / NTB scanpix

Artikkel av: Siri Knutsen Vosgraff
22. oktober 2018 - 07.40
An Error Occurred: Forbidden

Oops! An Error Occurred

The server returned a "403 Forbidden".

Something is broken. Please let us know what you were doing when this error occurred. We will fix it as soon as possible. Sorry for any inconvenience caused.

Bergenbio anslår å få en klinisk nyttegrad på 70 prosent og en total responsrate på 40 prosent på andrelinje NSCLC-pasienter i Keytruda/bemcentinib-kombinasjonsterapi, opplyses det i en melding.

Selskapet presenterer dataene ved ESMO 2018-kongressen i München.

Les hele meldingen her.

An Error Occurred: Forbidden

Oops! An Error Occurred

The server returned a "403 Forbidden".

Something is broken. Please let us know what you were doing when this error occurred. We will fix it as soon as possible. Sorry for any inconvenience caused.